Immetacyte Limited - Filleted accounts


Registered number
06709883
Immetacyte Limited
Unaudited Filleted Accounts
30 September 2019
Immetacyte Limited
Registered number: 06709883
Balance Sheet
as at 30 September 2019
As restated
Notes 2019 2018
£ £ £
Fixed assets
Tangible assets 3 426,349 117,029
Current assets
Debtors 4 1,008,933 559,151
Cash at bank and in hand 967,719 111,401
1,976,652 670,552
Creditors: amounts falling due within one year 5 (1,506,450) (351,505)
Net current assets 470,202 319,047
Total assets less current liabilities 896,551 436,076
Creditors: amounts falling due after more than one year 6 (9,723) (25,252)
Net assets 886,828 410,824
Capital and reserves
Called up share capital 31,652 31,652
Share premium 126,600 126,600
Profit and loss account 728,576 252,572
Shareholders' funds 886,828 410,824
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
R Hawkins
Director
Approved by the board on 19 November 2019
Immetacyte Limited
Notes to the Accounts
for the year ended 30 September 2019
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Equipment over 3 years straight line
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Leased assets
A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership. All other leases are classified as operating leases. The rights of use and obligations under finance leases are initially recognised as assets and liabilities at amounts equal to the fair value of the leased assets or, if lower, the present value of the minimum lease payments. Minimum lease payments are apportioned between the finance charge and the reduction in the outstanding liability using the effective interest rate method. The finance charge is allocated to each period during the lease so as to produce a constant periodic rate of interest on the remaining balance of the liability. Leased assets are depreciated in accordance with the company's policy for tangible fixed assets. If there is no reasonable certainty that ownership will be obtained at the end of the lease term, the asset is depreciated over the lower of the lease term and its useful life. Operating lease payments are recognised as an expense on a straight line basis over the lease term.
Research and development
Research and development costs are written off to profit and loss accounts as they are incurred.
Grant income
Grants that do not impose specified future performance-related conditions are recognised as per contractual obligations. Grants that do impose specified future performance-related conditions are recognised when the performance-related conditions are met. Grants received before the revenue recognition criteria are met are recognised as a liability.
Pensions
Contributions to defined contribution plans are expensed in the period to which they relate.
2 Employees 2019 2018
Number Number
Average number of persons employed by the company 23 14
3 Tangible fixed assets
Equipment
£
Cost
At 1 October 2018 327,782
Additions 430,933
At 30 September 2019 758,715
Depreciation
At 1 October 2018 210,753
Charge for the year 121,613
At 30 September 2019 332,366
Net book value
At 30 September 2019 426,349
At 30 September 2018 117,029
4 Debtors 2019 2018
£ £
Trade debtors 15,432 242,500
Corporation Tax 228,081 62,200
VAT Refund 54,404 28,659
Other debtors 711,016 225,792
1,008,933 559,151
5 Creditors: amounts falling due within one year 2019 2018
£ £
Bank loans and overdrafts - 13,889
Other loans 15,529 47,842
Trade creditors 104,266 223,407
Taxation and social security costs 82,868 31,349
Deferred income 1,004,546 -
Other creditors 299,241 35,018
1,506,450 351,505
6 Creditors: amounts falling due after one year 2019 2018
£ £
Other loans 9,723 25,252
7 Change of accounting policy
Immetacyte has a number of ongoing grants from Innovate UK. As processes have been established and increased certainty of receipt of claims, Immetacyte has therefore adopted the “accruals” basis for grant recognition rather than “receipt” basis. Income received in 2018/19 relating to 2017/18 has been added to prior year to provide comparatives.
8 Other information
Immetacyte Limited is a private company limited by shares and incorporated in England. Its registered office is:
48 Grafton Street
Manchester
England
M13 9XX
Immetacyte Limited 06709883 false 2018-10-01 2019-09-30 2019-09-30 VT Final Accounts July 2019 R Hawkins No description of principal activity 06709883 2017-10-01 2018-09-30 06709883 core:WithinOneYear 2018-09-30 06709883 core:AfterOneYear 2018-09-30 06709883 core:ShareCapital 2018-09-30 06709883 core:SharePremium 2018-09-30 06709883 core:RetainedEarningsAccumulatedLosses 2018-09-30 06709883 2018-10-01 2019-09-30 06709883 bus:PrivateLimitedCompanyLtd 2018-10-01 2019-09-30 06709883 bus:AuditExemptWithAccountantsReport 2018-10-01 2019-09-30 06709883 bus:Director40 2018-10-01 2019-09-30 06709883 1 2018-10-01 2019-09-30 06709883 2 2018-10-01 2019-09-30 06709883 core:PlantMachinery 2018-10-01 2019-09-30 06709883 countries:England 2018-10-01 2019-09-30 06709883 bus:FRS102 2018-10-01 2019-09-30 06709883 bus:FullAccounts 2018-10-01 2019-09-30 06709883 2019-09-30 06709883 core:WithinOneYear 2019-09-30 06709883 core:AfterOneYear 2019-09-30 06709883 core:ShareCapital 2019-09-30 06709883 core:SharePremium 2019-09-30 06709883 core:RetainedEarningsAccumulatedLosses 2019-09-30 06709883 core:PlantMachinery 2019-09-30 06709883 2018-09-30 06709883 core:PlantMachinery 2018-09-30 iso4217:GBP xbrli:pure